» Articles » PMID: 26157590

Dual Time Point (18)F-FDG PET/CT Imaging Identifies Bilateral Renal Tuberculosis in an Immunocompromised Patient with an Unknown Primary Malignancy

Overview
Date 2015 Jul 10
PMID 26157590
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

(18)F-FDG PET/CT imaging is an established imaging modality for cancer staging and response assessment. Its role in identifying infective and inflammatory pathologies from malignancy is debated. Dual time - point imaging is a refined technique used to overcome this interpretational dilemma. We present a 59 year old male with an unknown primary malignancy who was referred for a (18)F-FDG PET/CT imaging. Images revealed primary lung malignancy with co existing bilateral renal tuberculosis which otherwise would have gone amiss or would have been considered as metastases.

Citing Articles

A New Era for PET/CT: Applications in Non-Tumorous Renal Pathologies.

Moghrabi S, Abdlkadir A, Al-Hajaj N, Gnanasegaran G, Kumar R, Syed G J Clin Med. 2024; 13(16).

PMID: 39200774 PMC: 11355182. DOI: 10.3390/jcm13164632.


Acute Findings on FDG PET/CT: Key Imaging Features and How to Differentiate Them from Malignancy.

Li Y, Behr S Curr Radiol Rep. 2020; 8(11):22.

PMID: 32953250 PMC: 7486592. DOI: 10.1007/s40134-020-00367-x.


The impact of infection and inflammation in oncologic F-FDG PET/CT imaging.

Rahman W, Wale D, Viglianti B, Townsend D, Manganaro M, Gross M Biomed Pharmacother. 2019; 117:109168.

PMID: 31334700 PMC: 7104808. DOI: 10.1016/j.biopha.2019.109168.


Curious case of fever of unknown origin.

Bhatt M, Soneja M, Tripathi M, Biswas A BMJ Case Rep. 2018; 11(1).

PMID: 30567178 PMC: 6301645. DOI: 10.1136/bcr-2018-227258.

References
1.
Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K . Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001; 28(6):696-703. DOI: 10.1007/s002590100537. View

2.
Zhuang H, Pourdehnad M, Lambright E, Yamamoto A, Lanuti M, Li P . Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001; 42(9):1412-7. View